Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03215706
Title	A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC (CheckMate 9LA)
Acronym	CheckMate 9LA
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Bristol-Myers Squibb
Indications	lung non-small cell carcinoma lung squamous cell carcinoma
Therapies	Carboplatin + Cisplatin + Paclitaxel + Pemetrexed Disodium Ipilimumab + Nivolumab
Age Groups:	adult \| senior
Covered Countries	USA \| ROU \| POL \| ITA \| IRL \| GBR \| FRA \| ESP \| DEU \| CAN \| BRA \| BEL \| AUS \| ARG